Safety, tolerability, pharmacokinetics(PK) and pharmacodynamics(PD) of HSK31858,a novel DPP-1 inhibitor in healthy volunteers:a phase I clinical trial

被引：0
|
作者：
Hou, Jie [1 ]
Guan, Wei Jie [2 ]
Li, Fang Qiong [3 ]
Zeng, Wei Fang [3 ]
Liu, Han Mo [3 ]
机构：
[1] PKUcare Luzhong Hosp, Zibo, Peoples R China
[2] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Dis, State Key Lab Resp Dis,Natl Clin Res Ctr Resp Dis, Guangzhou, Peoples R China
[3] Haisco Pharmaceut Grp Co Ltd, Chengdu, Peoples R China
来源：
EUROPEAN RESPIRATORY JOURNAL | 2023年 / 62卷
关键词：
D O I：
10.1183/13993003.congress-2023.PA2836
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy Volunteers
    Raja, Shruti M.
    Guptill, Jeffrey T.
    Mack, Michelle
    Peterson, Marni
    Byard, Stephen
    Twieg, Robert
    Jordan, Lynn
    Rich, Natalie
    Castledine, Richard
    Bourne, Samuel
    Wilmshurst, Martin
    Oxendine, Sarah
    Avula, Satya G. C.
    Zuleta, Helen
    Quigley, Paul
    Lawson, Sheila
    McQuaker, Stephen J.
    Ahmadkhaniha, Reza
    Appelbaum, Lawrence G.
    Kowalski, Kevin
    Barksdale, Chineta T.
    Gufford, Brandon T.
    Awan, Asaad
    Sancho, Alfredo R.
    Moore, Max C.
    Berrada, Karim
    Cogan, Gregory B.
    DeLarosa, Jesse
    Radcliffe, Jeanne
    Pao, Maryland
    Kennedy, Michelle
    Lawrence, Quentin
    Goldfeder, Lisa
    Amanfo, Leslie
    Zanos, Panos
    Gilbert, Jessica R.
    Morris, Patrick J.
    Moaddel, Ruin
    Gould, Todd D.
    Zarate, Carlos A.
    Thomas, Craig J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024,
  • [42] EVALUATION OF SINGLE DOSE SAFETY, PHARMACOKINETICS (PK), AND PHARMACODYNAMICS (PD) OF A NOVEL HUMAN ANTI-IL6 MONOCLONAL ANTIBODY PF-04236921 IN PHASE I HEALTHY VOLUNTEERS.
    Li, C.
    Sridharan, S.
    Foge, R.
    Bradley, J.
    Riese, R.
    Labadie, R.
    Menon, S.
    Gupta, P.
    Krishnaswami, S.
    Beebe, J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S55 - S56
  • [43] Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers
    Weisel, Kathleen
    Scott, Nicola E.
    Tompson, Debra J.
    Votta, Bartholomew J.
    Madhavan, Sujith
    Povey, Kat
    Wolstenholme, Allen
    Simeoni, Monica
    Rudo, Todd
    Richards-Peterson, Lauren
    Sahota, Tarjinder
    Wang, J. Gene
    Lich, John
    Finger, Joshua
    Verticelli, Adeline
    Reilly, Michael
    Gough, Peter J.
    Harris, Philip A.
    Bertin, John
    Wang, Mei-Lun
    [J]. PHARMACOLOGY RESEARCH & PERSPECTIVES, 2017, 5 (06):
  • [44] A PHASE 1 STUDY IN HEALTHY VOLUNTEERS EXPLORING THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ATI-450: A NOVEL ORAL MK2 INHIBITOR
    Schnyder, J.
    Monahan, J.
    Smith, W.
    Hope, H.
    Kelly, D.
    Burt, D.
    Huff, E.
    Kaul, A.
    Hildebrand, A.
    Burnette, B.
    Klug, N.
    Bangs, M.
    Gordon, D.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1006 - 1006
  • [45] Safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a dual GLP-1/GIP receptor agonist (HRS9531) in healthy subjects
    Wen, Q.
    He, K.
    Wei, F.
    Chen, H.
    Zhang, Y.
    Sheng, Z.
    Yin, L.
    [J]. DIABETOLOGIA, 2023, 66 (SUPPL 1) : S326 - S327
  • [46] Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers
    Litzenburger, Tobias
    Steffgen, Juergen
    Benediktus, Ewald
    Mueller, Fabian
    Schultz, Armin
    Klein, Elliott
    Ramanujam, Meera
    Harcken, Christian
    Gupta, Alpana
    Wu, Jing
    Wiebe, Sabrina
    Li, Xiujiang
    Flack, Mary
    Padula, Steven J.
    Visvanathan, Sudha
    Huennemeyer, Andreas
    Hui, Jianan
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (04) : 1824 - 1838
  • [47] A phase I study to evaluate the safety, tolerability, and pharmacokinetics of a novel, potent GABA analog HSK16149 in healthy Chinese subjects
    Chen, Qian
    Wu, Qingqing
    Song, Rong
    Wang, Yating
    Zhang, Mengqi
    Li, Fangqiong
    Zeng, Weifang
    Wang, Wei
    Jia, Jingying
    Yu, Chen
    Liu, Yanmei
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [48] The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers
    Moschetti, Viktoria
    Kim, Maria
    Sand, Michael
    Wunderlich, Glen
    Andersen, Grit
    Feifel, Ulrich
    Jang, In-Jin
    Timmer, Wolfgang
    Rosenbrock, Holger
    Boland, Katja
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2018, 28 (05) : 643 - 655
  • [49] Phase 1 Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers
    Merica, VarshaIyer Elizabeth
    Ronseaux, Sebastien
    Gamache, Tressa
    Mulrow, Nancy J.
    Belcijan, Anja
    Callaghan, Michael U.
    [J]. BLOOD, 2021, 138
  • [50] A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers
    Printz, Marie A.
    Dychter, Samuel S.
    DeNoia, Emanuel P.
    Harrigan, Rena
    Sugarman, Barry J.
    Zepeda, Monica
    Souratha, Jennifer
    Kang, David W.
    Maneval, Daniel C.
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2020, 93
12345